Kodiform Therapeutics

Kodiform Therapeutics is a drug discovery company developing first-in-class small molecule inhibitors against intrinsically disordered protein targets in cancer, a class historically considered undruggable due to the absence of stable binding pockets.

The company uses intracellular antibody technology to identify and characterise binding sites on disordered proteins, providing a structural and biophysical basis for small molecule drug design.

Initial programmes focus on transcription factors and other high-value oncology targets.